155 related articles for article (PubMed ID: 21406409)
1. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
2. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
4. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
5. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
6. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
7. The United States Food and Drugs Administration approves a generic enoxaparin.
Ofosu FA
Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
9. Recommendations on biosimilar low-molecular-weight heparins.
Harenberg J; Kakkar A; Bergqvist D; Barrowcliffe T; Casu B; Fareed J; Mismetti P; Ofosu FA; Raake W; Samama M; Schulman S;
J Thromb Haemost; 2009 Jul; 7(7):1222-5. PubMed ID: 19323788
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
11. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
[TBL] [Abstract][Full Text] [Related]
12. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
Haas S
Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
Prandoni P; Simioni P; Pagnan A
Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparins in clinical practice.
Hunt D
South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394
[TBL] [Abstract][Full Text] [Related]
16. Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial.
Gomes M; Ramacciotti E; Henriques AC; Araujo GR; Szultan LA; Miranda F; Thethi I
Clin Appl Thromb Hemost; 2011; 17(6):633-9. PubMed ID: 21949036
[TBL] [Abstract][Full Text] [Related]
17. New and generic anticoagulants and biosimilars: safety considerations.
Kalodiki E; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparins in the outpatient management of venous thromboembolism.
Bick RL
Semin Thromb Hemost; 1999; 25 Suppl 3():97-9. PubMed ID: 10549723
[TBL] [Abstract][Full Text] [Related]
19. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.
Cohen M; Jeske WP; Nicolau JC; Montalescot G; Fareed J
J Thromb Thrombolysis; 2012 Apr; 33(3):230-8. PubMed ID: 22234748
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
Ornstein DL; Hong-Dice YG; Papini JR
Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]